Dual Agonist · Metabolic Research · COA Verified
For research and laboratory use only. Not for human consumption. By purchasing, you confirm you are a qualified researcher.
For Research Purposes Only. Not approved for human consumption.
GLP2 is a synthetic dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — a first-in-class twincretin peptide. In Phase 3 trials, GLP2 achieved up to 22.5% weight loss, surpassing single-mechanism GLP-1 agonist results and establishing dual agonism as superior to single GLP-1 activation for metabolic endpoints. It serves as a critical comparator in research between single-mechanism (GLP1) and triple-mechanism (GLP3) approaches.
Q: What makes GLP2 unique?
A: First dual GIP/GLP-1 agonist ('twincretin') studied in Phase 3 trials. Most metabolic peptides target one receptor. GLP2 targets two — establishing dual agonism as superior to single-mechanism approaches.
Q: What were the Phase 3 trial results?
A: GLP2 achieved up to 22.5% weight loss in Phase 3 trials — exceeding single-agonist results of ~15% and setting the stage for triple agonists like GLP3 to push further.
Q: How does GLP2 fit between GLP1 and GLP3?
A: It is the middle tier: GLP1 = single agonist (GLP-1 only); GLP2 = dual agonist (GLP-1 + GIP); GLP3 = triple agonist (GLP-1 + GIP + Glucagon). Research often compares all three.
Related Research: GLP1 Research Peptide | GLP3 Research Peptide | 2026 Metabolic Research Update | Cagrilintide Research Peptide | Retatrutide Complete Research Guide | Are Research Peptides Legal? | What Is a COA?
For laboratory research use only. Not for human consumption. Not evaluated by the FDA.
| Lot # | Size | Test Date | COA |
|---|---|---|---|
| ARC-TZ30-002 | 30mg | Jun 23, 2026 | View PDF |
